TNFRSF8 and neoplasm: Alternatively, CD30‐positive membranous vesicles liberated from the surface of CD30‐positive tumour cells may translocate the target antigen to CD30‐negative bystander cells and facilitates brentuximab vedotin binding and consecutive cellular kill as recently shown in HL 19.